RNA Therapeutics Beyond COVID Vaccines: What Indian Clinicians Should Expect in 2026

The Second Wave: RNA Therapeutics Beyond COVID Vaccines and What Indian Clinicians Should Expect First

Introduction

The success of mRNA COVID-19 vaccines introduced the world to RNA-based medicine, but vaccines represent only the beginning of a much broader therapeutic revolution. RNA therapeutics are now transforming cardiovascular medicine, oncology, rare genetic disorders, neurology, and metabolic diseases through targeted gene silencing, protein replacement, and RNA editing.

For Indian clinicians, this shift is no longer theoretical. Several RNA therapies are already approved internationally, while many others are expected to reach Indian clinical practice over the next three to five years through regulatory approvals and clinical trials.

Why RNA Therapeutics Matter Beyond COVID-19

Unlike conventional drugs that influence proteins indirectly, RNA therapeutics act earlier in the biological pathway by controlling how proteins are produced inside cells.

The major RNA therapeutic platforms include:

Small Interfering RNA (siRNA)

• Silences disease-causing genes by degrading messenger RNA (mRNA)
• Long-lasting effects with dosing every few months
• Liver-targeted delivery through GalNAc conjugation
• Widely used for cardiovascular and metabolic disorders

Antisense Oligonucleotides (ASOs)

• Bind directly to RNA to block or modify protein production
• Can alter RNA splicing or promote RNA degradation
• Particularly valuable for neurological and rare genetic diseases

Messenger RNA (mRNA)

• Delivers temporary instructions for cells to produce therapeutic proteins
• Used for protein replacement therapies and personalised cancer vaccines
• Does not permanently alter DNA

RNA Editing

• Corrects faulty RNA transcripts without changing the genome
• Uses naturally occurring ADAR enzymes
• Represents one of the newest advances in precision medicine

Cardiovascular RNA Therapeutics Will Arrive First

Among all RNA therapies, cardiovascular medicine is expected to benefit the earliest in India due to the country's enormous burden of premature heart disease.

Inclisiran for LDL Cholesterol Reduction

Inclisiran is a GalNAc-conjugated siRNA that silences PCSK9 production in the liver, allowing LDL receptors to recycle more effectively.

Key benefits include:

• Around 50% LDL cholesterol reduction
• Twice-yearly maintenance dosing
• Better treatment adherence than daily oral medications
• Expanded FDA approval as first-line therapy in 2025

Lp(a)-Lowering RNA Drugs

Elevated Lipoprotein(a) is highly prevalent among South Asians and significantly increases cardiovascular risk.

Several late-stage RNA therapies are nearing approval:

• Pelacarsen
• Olpasiran
• Lepodisiran
• Zerlasiran

Phase 2 studies have demonstrated Lp(a) reductions approaching 80–95%. If ongoing outcome trials confirm reduced cardiovascular events, these drugs could become one of the biggest advances in preventive cardiology for Indian patients.

Neurological Diseases Are Entering the RNA Era

RNA therapeutics are changing the management of inherited neurological disorders that previously had only supportive care.

Spinal Muscular Atrophy (SMA)

Nusinersen remains the leading example of RNA therapy in neurology by correcting abnormal RNA splicing to restore functional SMN protein.

For India, expanding newborn screening programs make early diagnosis increasingly important because treatment before symptom onset can preserve near-normal motor function.

Expanding Neurology Pipeline

Additional RNA therapies are being investigated for:

• Huntington's disease
• Amyotrophic lateral sclerosis (ALS)
• Alzheimer's disease
• Duchenne muscular dystrophy
• Myotonic dystrophy

Liver-Targeted RNA Medicines Continue to Expand

The liver has become the ideal target organ for RNA therapeutics because GalNAc technology delivers drugs directly into hepatocytes with remarkable precision.

Approved examples include:

Givosiran

Treats acute hepatic porphyria by preventing toxic metabolite accumulation.

Lumasiran

Reduces oxalate production in primary hyperoxaluria, preventing progressive kidney damage.

Olezarsen

Recently approved for familial chylomicronemia syndrome and severe hypertriglyceridemia associated with recurrent pancreatitis.

RNA Editing Opens a New Frontier

The first successful clinical demonstration of RNA editing has been achieved using WVE-006 for alpha-1 antitrypsin deficiency.

Unlike gene editing, RNA editing:

• Is temporary
• Is reversible
• Does not modify DNA
• May eventually treat numerous single-gene disorders

Although immediate clinical relevance for India is limited, the technology represents an important long-term platform for precision medicine.

mRNA Cancer Vaccines Are Moving Toward Clinical Practice

Personalised mRNA cancer vaccines are among the most exciting developments in oncology.

After sequencing a patient's tumour, customised mRNA vaccines are produced to stimulate immune cells against tumour-specific mutations.

Current leading indications include:

• Melanoma
• Non-small cell lung cancer
• Bladder cancer
• Renal cell carcinoma

Large academic centres such as Tata Memorial Hospital and AIIMS are expected to become the earliest Indian sites participating in personalised vaccine programs and international clinical trials.

Emerging RNA Technologies

The next generation of RNA therapeutics is already under development.

Circular RNA (circRNA)

CircRNA provides longer-lasting protein expression than conventional mRNA, making it attractive for chronic diseases.

Self-Amplifying RNA (saRNA)

Self-amplifying RNA produces larger amounts of therapeutic RNA from very small doses, potentially reducing manufacturing costs and improving affordability for countries like India.

What Indian Clinicians Should Prepare for

The most likely RNA therapeutics to enter Indian clinical practice over the next few years include:

Cardiovascular Medicine

• Inclisiran for LDL reduction
• Lp(a)-lowering RNA therapies

Rare Cardiac Diseases

• siRNA therapies for hereditary transthyretin amyloidosis (hATTR)

Oncology

• Personalised mRNA cancer vaccines alongside checkpoint inhibitors

Paediatric Neurology

• ASO therapies for spinal muscular atrophy

Rare Metabolic Disorders

• Givosiran
• Lumasiran
• Olezarsen

Clinicians should focus on recognising eligible patients early, understanding appropriate genetic testing, and preparing for referral pathways as these therapies become available.

RNA Therapeutics in India: Current Regulatory Status

Most RNA therapeutics remain unavailable through routine clinical practice in India.

Broader access will depend on:

• CDSCO regulatory approvals
• Expansion of Indian oligonucleotide manufacturing
• Growth of lipid nanoparticle production
• Rare disease reimbursement policies
• Participation in multinational clinical trials

Several Indian pharmaceutical companies are already investing heavily in RNA manufacturing capabilities, suggesting a gradual expansion of domestic availability.

Conclusion

RNA therapeutics have rapidly evolved from pandemic vaccines into one of modern medicine's fastest-growing therapeutic platforms. Cardiovascular disease, oncology, neurology, and rare genetic disorders are expected to be the first major specialties transformed in India. For clinicians, understanding RNA-based medicines is becoming an essential component of contemporary medical practice rather than preparation for a distant future.

#RNATherapeutics #PrecisionMedicine